EPZ004777
目录号 : GC13383
EPZ004777 作为一种有效的表观遗传调节剂，可以逆转 TGF-β1 诱导的 T 调节细胞，可用于治疗多种免疫疾病。
Cas No.:1338466-77-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
EPZ004777, as a potent epigenetic modulators, can reverse TGF-β1 induced T regulatory cells and may be used to treat diverse immune disorders[1].
In vitro, EPZ004777 has concentration-dependent inhibition of DOT1L enzyme activity with an IC50 of 400 ± 100 pM. In vitro experiment it shown that in MV4-11 cells incubated with 3 μM EPZ004777, a concentration sufficient for maximal cellular DOT1L inhibition. After treatment with 1 day, there is a apparently modest reduction in H3K79me2 levels, but full depletion took 4–5 days. In vitro efficacy test it exhibited that treatment with 3 μM EPZ004777 caused a concentration-dependent decrease of both transcripts in each cell line with IC50 s of approximately 700 nM.[2] In vitro, treatment with 30 μM and 50 μM EPZ004777 obviously decreased cell viability of SW480 cells in a dose-dependent manner. Also 30 μM, 50 μM, and 70 μM EPZ004777 treatment in a dose-dependent manner inhibited the cell viability of HCT116 cells.[3] In vitro, EPZ004777 could also inhibit the proliferation and induce the differentiation of YBT-5 cells[4].
In vivo, nude mice bearing MV4-11 xenograft tumors loaded with a 50 mg/ml solution of EPZ004777, H3K79me2 levels were markedly decreased in tumors from mice treated with EPZ004777 compared to untreated controls.[2] In vivo experiment it demonstated that treatment with 10 and 50?mg/kg EPZ004777 via subconjunctival injection could alleviate corneal injury and opacity.[5].
References:
[1]Premkumar K, Shankar BS. Identification of EPZ004777 and FG2216 as inhibitors of TGF-β1 induced Treg cells by screening a library of epigenetic compounds. Life Sci. 2022 Jul 15;301:120643.
[2]Daigle SR, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011 Jul 12;20(1):53-65.
[3]Yang L, et al. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer. Clin Epigenetics. 2019 Dec 30;11(1):199.
[4]Wang Z, et al. Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion. Hematol Oncol. 2019 Dec;37(5):617-625.
[5]Wan S, et al. Dot1l Aggravates Keratitis Induced by Herpes Simplex Virus Type 1 in Mice via p38 MAPK-Mediated Oxidative Stress. Oxid Med Cell Longev. 2021 Feb 15;2021:6612689.
EPZ004777 作为一种有效的表观遗传调节剂，可以逆转 TGF-β1 诱导的 T 调节细胞，可用于治疗多种免疫疾病[1]。
在体外，EPZ004777 对 DOT1L 酶活性具有浓度依赖性抑制作用，IC50 为 400 ± 100 pM。体外实验表明，在 MV4-11 细胞中与 3 μM EPZ004777 孵育，该浓度足以实现最大细胞 DOT1L 抑制。处理 1 天后，H3K79me2 水平明显适度降低，但完全耗尽需要 4-5 天。体外功效测试表明，用 3 μM EPZ004777 处理会导致每个细胞系中两种转录物的浓度依赖性降低，IC50 s 约为 700 nM。[2] 在体外，用 30 μM 和 50 μM EPZ004777 处理以剂量依赖性方式显着降低 SW480 细胞的细胞活力。此外，30 μM、50 μM 和 70 μM EPZ004777 剂量依赖性抑制 HCT116 细胞的细胞活力。[3] 在体外，EPZ004777 还可以抑制增殖并诱导分化YBT-5细胞[4].
在体内，荷载 MV4-11 异种移植肿瘤的裸鼠加载了 50 mg/ml EPZ004777 溶液，与未处理的对照组相比，用 EPZ004777 处理的小鼠的肿瘤中 H3K79me2 水平显着降低。[2] 体内实验表明，通过结膜下注射 10 和 50mg/kg EPZ004777 可以减轻角膜损伤和混浊。[5].
| Cell experiment [1]: | |
|
Cell lines |
RAW264.7 cells |
|
Preparation Method |
DOT1L enzyme inhibition enhances OC fusion and resorption ability a RAW264.7 cells pretreated with DMSO or the indicated concentrations of DOT1L inhibitors (EPZ5676 and EPZ004777) and stimulated with RANKL for 60 h. OCs were fixed and stained for TRAP. |
|
Reaction Conditions |
1 and 10 µM; 5 days |
|
Applications |
Treatment with DOT1L inhibitors (EPZ5676 and EPZ004777) increased the proportion and number of large OCs, which was approximately twice that observed in the control group. Furthermore, no significant difference was observed between the effects of treatment at 1 and 10 µM of the DOT1L inhibitors. |
| Animal experiment [2]: | |
|
Animal models |
BALB/c-nu mice |
|
Preparation Method |
1 × 106 HCT116 cells were subcutaneously injected in the left flank of the BALB/c-nu mice. After tumor pumped, the mice were randomly divided into two groups. One group was treated with PBS with 10% DMSO, while the other group was treated with EPZ004777 (100 mg/kg/day, diluted into PBS with 10% DMSO) for 16 days. At the termination of the experiment, tumors were removed and weighed. |
|
Dosage form |
100 mg/kg/day; i.p. |
|
Applications |
The results showed that the tumor volumes and weights of all EPZ004777-treated tumors in the nude mice were significantly smaller and lighter than the control groups, respectively. |
|
References: [1]. Gao Y, Ge W. The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis. Cell Death Dis. 2018 Jan 18;9(2):33. [2]. Yang L, et al. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer. Clin Epigenetics. 2019 Dec 30;11(1):199. |
|
| Cas No. | 1338466-77-5 | SDF | |
| 化学名 | 1-[3-[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl-propan-2-ylamino]propyl]-3-(4-tert-butylphenyl)urea | ||
| Canonical SMILES | CC(C)N(CCCNC(=O)NC1=CC=C(C=C1)C(C)(C)C)CC2C(C(C(O2)N3C=CC4=C3N=CN=C4N)O)O | ||
| 分子式 | C28H41N7O4 | 分子量 | 539.67 |
| 溶解度 | ≥ 27 mg/mL in DMSO, ≥ 94.6 mg/mL in EtOH with ultrasonic | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.853 mL | 9.2649 mL | 18.5298 mL |
| 5 mM | 0.3706 mL | 1.853 mL | 3.706 mL |
| 10 mM | 0.1853 mL | 0.9265 mL | 1.853 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet